title: Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
abstract: Plasmablastic lymphoma (PBL) is a rare and aggressive CD20-negative lymphoma. Despite improvements of the biology behind PBL, it still represents a challenge from the diagnostic and therapeutic perspectives for pathologists and clinicians. PBL is characterized by high rates of relapse and short median survival with standard approaches. Here, we report the use of the combination of bortezomib and infusional etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (V-EPOCH) in three patients with PBL; two were HIV-positive and one was HIV-negative. All three patients obtained a durable complete response to V-EPOCH with survival times of 24, 18 and 12 months respectively.
authors.affiliation: Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
authors.forename: Jorge J
authors.initials: JJ
authors.lastname: Castillo
authors.forename: John L
authors.initials: JL
authors.lastname: Reagan
authors.forename: William M
authors.initials: WM
authors.lastname: Sikov
authors.forename: Eric S
authors.initials: ES
authors.lastname: Winer
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D019788:Fluorodeoxyglucose F18; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D049268:Positron-Emission Tomography; D011241:Prednisone / Q000627:therapeutic use; D011719:Pyrazines / Q000008:administration & dosage*; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D001897:Boronic Acids; D011719:Pyrazines; D019788:Fluorodeoxyglucose F18; D014750:Vincristine; D000069286:Bortezomib; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: EPOCH; Plasmablastic lymphoma; bortezomib